Reported about 12 hours ago
Thermo Fisher Scientific has announced its acquisition of Solventum's purification and filtration business for approximately $4.1 billion, a move aimed at enhancing its bioproduction capabilities in drug development. The deal is expected to close by the end of 2025, and it resulted in a 2% rise in Solventum's shares during premarket trading.
Source: YAHOO